Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sol-Gel Technologies

6.92
+0.00990.14%
Volume:1.63K
Turnover:11.33K
Market Cap:19.28M
PE:-1.99
High:7.15
Open:7.15
Low:6.87
Close:6.91
Loading ...

Sol-Gel Technologies Reports Q1 2025 Financial Results

TIPRANKS
·
23 May

Sol-Gel Technologies Reports Q1 2025: Revenue Doubles to $1M, Net Loss Widens to $8.8M, EPS Loss Increases to $3.2

Reuters
·
23 May

Sol Gel Technologies: Q1 Net Loss per Share $3.2

THOMSON REUTERS
·
23 May

Sol-Gel Reports First Quarter 2025 Results

THOMSON REUTERS
·
23 May

Sol-Gel Technologies Ltd. Q1 Net Income USD -8.8 Million

THOMSON REUTERS
·
23 May

Press Release: Sol-Gel Reports First Quarter 2025 Results

Dow Jones
·
23 May

Sol-Gel Technologies Ltd. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Reuters
·
23 May

Sol Gel Technologies Ltd - Sol-Gel Announces Reverse Share Split at 10-for-1 Ratio

THOMSON REUTERS
·
01 May

Sol-Gel Announces Reverse Share Split

THOMSON REUTERS
·
01 May

Sol-Gel Announces Reverse Share Split

GlobeNewswire
·
01 May

Sol-Gel Technologies files $120M mixed securities shelf

TIPRANKS
·
30 Apr

Sol Gel Technologies Ltd Files for Mixed Shelf of up to $120 Mln - SEC Filing

THOMSON REUTERS
·
30 Apr

Mayne Pharma Anticipates FY25 Underlying EBITDA In Range Of A$47 Million To A$51 Million

Reuters
·
22 Apr

BRIEF-Sol-Gel And Mayne Pharma Announce The Purchase Of Epsolay And Twyneo In The U.S.

Reuters
·
17 Apr

Sol-Gel, Mayne Pharma enter product purchase agreement

TIPRANKS
·
17 Apr

Sol-Gel- to Receive $16 Million During 2025

THOMSON REUTERS
·
17 Apr

Sol-Gel and Mayne Pharma Announce the Purchase of Epsolay® and Twyneo® in the U.S.

THOMSON REUTERS
·
17 Apr

Sol-Gel- Sgt-610 Phase Iii Trial Top-Line Results Expected Q4 2026

THOMSON REUTERS
·
17 Apr

Press Release: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY(R) and TWYNEO(R) in the U.S.

Dow Jones
·
17 Apr

Sol-Gel Technologies Approves Reverse Share Split and Compensation Policy Renewal

TIPRANKS
·
02 Apr